The impact of fatty acid synthase on HSV-1 infection dynamics
Article 2025 en
Authors
CA
Camilla Albano
LT
Linda Trifirò
WH
Weronika Hewelt-Belka
Abstract
1 min read
Herpes simplex virus type-1 (HSV-1) is a widespread human pathogen that relies on host cell pathways, including those involved in metabolism to support replication. Here, we demonstrate that de novo lipogenesis is essential for HSV-1 infectivity. Specifically, HSV-1 infection upregulates fatty acid synthase (FASN) expression, accompanied by a marked increase in lipids and a differential lipid species distribution. Conversely, silencing FASN or applying FASN inhibitors (i.e., CMS121 and C75) markedly reduces the infectivity of newly released HSV-1 virions, suggesting that, while initial replication remains unaffected, FASN is crucial for maintaining virion structure and facilitating entry into host cells. Additionally, we show that a source of lipid-rich external factors provided by fetal bovine serum significantly increases HSV-1 infectivity. Specifically, HSV-1 infection enhanced CD36-mediated fatty acid uptake, especially in FASN-depleted cells, compensating for reduced lipogenesis. Blocking CD36 function with SSO further decreased viral infectivity, demonstrating the critical role of lipid uptake in HSV-1 life cycle. Altogether, our findings reveal how HSV-1 manipulates lipid metabolism, offering insights into its association with chronic disease and therapeutic intervention.
Richard G. Carroll, Zbigniew Zasłona, Silvia Galván-Peña, Emma Koppe, Daniel C. Sévin, Stefano Angiari, Martha Triantafilou, Kathy Triantafilou, Louise K. Modis, Luke O'neill
Sam Sheppard, Katja Srpan, Wendy Lin, Mariah Lee, Rebecca B. Delconte, Mark Owyong, Peter Carmeliet, Daniel M. Davis, João B. Xavier, Katharine C. Hsu, Joseph C. Sun
Santiago Díaz‐Moralli, Esther Aguilar, Silvia Marín, Johannes F. Coy, Mieke Dewerchin, Maciek R. Antoniewicz, Óscar Meca‐Cortés, Leen Notebaert, Bart Ghesquière, Guy Eelen, Timothy M. Thomson, Peter Carmeliet, Marta Cascante
Discussion(0)
No comments yet. Be the first to comment.